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Abstract
Background: Selective decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination
(SOD) reduce colonization with antibiotic-resistant Gram-negative bacteria (ARGNB), incidence of nosocomial
infections and improve survival in ICU patients. The effect on bacterial gut colonization might be caused by growth
suppression by antibiotics during SDD/SOD. We investigated intestinal colonization with ARGNB after discharge
from ICU and discontinuation of SDD or SOD.
Methods: We performed a prospective, observational follow-up study in regular hospital wards of three teaching
hospitals in the Netherlands in patients discharged from the ICU, who were participating in a cluster randomized
trial comparing SDD with SOD. We determined rectal carriage with ARGNB at ICU discharge (time (T) = 0) and 3, 6
and 10 days after discharge. The primary endpoint was time to first colonization with ARGNB that was not present
at T = 0. Bacteria that are intrinsically resistant to antibiotics were not included in the primary analysis, but were
included in post-hoc analysis.
Results: Of 1370 patients screened for inclusion, 996 patients had samples at T = 0 (507 after SDD and 489 after
SOD). At ICU discharge, the prevalence of intestinal carriage with any ARGNB was 22/507 (4.3%) after SDD and
87/489 (17.8%) after SOD (p < 0.0001): 426 (SDD) and 409 (SOD) patients had at least one follow-up sample for
analysis. The hazard rate for acquiring carriage of ARGNB after discontinuation of SDD, compared to SOD, in the
ICU was 0.61 (95% CI 0.40–0.91, p = 0.02), and cumulative risks of acquisition of at least one ARGNB until day 10
were 13% (SDD) and 18% (SOD). At day 10 after ICU discharge, the prevalence of intestinal carriage with ARGNB
was 11.3% (26/230 patients) after SDD and 12.5% (28/224 patients) after SOD (p = 0.7). In post-hoc analysis of all
ARGNB, including intrinsically resistant bacteria, colonization at ICU discharge was lower after SDD (4.9 vs. 22.3%,
p < 0.0001), but acquisition rates after ICU discharge were similar in both groups.
Conclusions: Intestinal carriage at ICU discharge and the acquisition rate of ARGNB after ICU discharge are lower
after SDD than after SOD. The prevalence of intestinal carriage with ARGNB at 10 days after ICU discharge was
comparable in both groups, suggesting rapid clearance of ARGNB from the gut after ICU discharge.
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Background
Selective decontamination of the digestive tract (SDD)
and selective oropharyngeal decontamination (SOD) are
prophylactic antibiotic interventions for patients in in-
tensive care units (ICUs). They consist of enteral appli-
cation of non-absorbable antimicrobial agents, most
often amphotericin B, tobramycin and colistin, aiming to
eradicate yeasts, Staphylococcus aureus and (facultative)
aerobic Gram-negative bacteria. SDD includes topical
antibiotics applied daily to the mouth and the stomach
during the whole ICU admission, in combination with a
short initial course of intravenous antibiotics. SOD only
applies antibiotics to the mouth. Use of SDD or SOD
has been shown to reduce the incidence of
ventilator-associated pneumonia (VAP) and to improve
patient survival [1–5].
SDD and SOD imply daily administration of topical an-
tibiotics during ICU stay. Prolonged use of antibiotics is
generally associated with an increased risk of antibiotic re-
sistance, especially in critically ill ICU patients. Yet, SDD
and SOD have not been associated with increased resist-
ance of bacteria colonizing the digestive tract [2, 3, 6, 7].
In fact, in recent large studies from the Netherlands, anti-
biotic resistance in Gram-negative bacteria colonizing the
digestive tract was reduced during SOD and even more
during SDD [2, 3]. Possible, but unproven explanations
for this decrease in resistance during use of SDD and
SOD include decreased incidence of nosocomial infections
with a concomitant decrease in the use of systemic antibi-
otics during SDD and SOD, very high enteral concentra-
tions of tobramycin and colistin that may even eradicate
or suppress aerobic Gram-negative bacteria classified as
resistant based on the determined minimal inhibitory con-
centrations [6], or masking the presence of resistant bac-
teria in culture medium due to the topical antibiotics
present in fecal samples [8]. If topical antibiotics in the in-
testinal tract suppress bacterial growth without eradica-
tion or if these antibiotics result in false-negative culture
results, rapid emergence of resistant bacteria after discon-
tinuation of SDD, usually after patient discharge from
ICU, could be expected.
So far, all analyses on the effects of SDD and SOD on
antibiotic resistance have been restricted to the period of
administration of prophylactic antibiotics. Debate con-
tinues on the effects of SDD and SOD on the emergence
of antibiotic resistance [5]. We, therefore, quantified the
acquisition rates of rectal recolonization with resistant
aerobic Gram-negative bacteria in patients during the
first 10 days after discharge from ICU and discontinu-
ation of SDD or SOD.
Patients
This trial has been registered in the Netherlands Trial
Registry (number NTR3311). It was a prospective, observa-
tional study in medical and surgical ICU patients in three
teaching hospitals in the Netherlands (Academic Medical
Center, Amsterdam, University Medical Center, Utrecht,
and Leiden University Medical Center, Leiden), performed
in parallel to a Dutch 16-center cluster-randomized trial
evaluating the effects of SDD and SOD on colonization
with antibiotic resistant Gram-negative bacteria in respira-
tory and perineal samples. In this trial, performed between
August, 2009 and February, 2013 ICUs crossed over from
using SDD to SOD or from SOD to SDD in all patients
with an expected ICU length of stay > 48 h [9]. When
crossing over from SDD to SOD or from SOD to SDD
there was a 1-month washout period during which no pa-
tients were included in thisstudy.
From September 2010 to April 2013, all patients dis-
charged from the ICUs of three hospitals were eligible
for inclusion if they had received SDD or SOD treatment
for more than 4 days. Exclusion criteria were age youn-
ger than 18 years, and treatment with enteral antibiotics
other than SDD or SOD during ICU stay. If patients had
been admitted to ICU more than one time during hos-
pital admission, only the hospitalization period after the
last ICU admission was eligible.
Methods
The SDD regimen was identical to that used in previous
trials and consisted of oropharyngeal application (every
6 h) of approximately 0.5 g of a paste containing colistin,
tobramycin and amphotericin B each in a 2% concentra-
tion. In patients with a tracheostomy the same paste was
applied around the tracheostomy. In addition, a 10 ml
suspension containing 100 mg colistin, 122 mg tobra-
mycin and 500 mg amphotericin B was given via the
nasogastric tube four times daily until ICU discharge. In
patients with a duodenal tube or jejunostomy, 5 ml of
the suspension was given via the gastric tube and the
remaining 5 ml via the duodenal tube or jejunostomy.
Patients with colostomy or ileostomy received SDD
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suppositories (containing 100 mg colistin, 61 mg tobra-
mycin and 200 mg amphotericin B) twice daily in the
distal part of the gut. In addition, cefotaxime (1000 mg,
every 6 h) was administered intravenously during the
first 4 days. Other intravenous antibiotics were adminis-
tered therapeutically if clinically indicated. The SOD
regimen consisted of oropharyngeal application of the
same paste as used for SDD. In patients with tracheostomy
the paste was also applied around the tracheostomy. No
other prophylactic antibiotics were administered. Intraven-
ous antibiotics were given only if clinically indicated.
Rectal colonization with any resistant aerobic
Gram-negative bacteria was determined by rectal swab
cultures at time points 0, 3, 6 and 10 days after discharge
from the ICU. Samples were screened for presence of re-
sistant aerobic Gram-negative bacteria by selective
media (ChromID ESBL agar; McConkey agar with tobra-
mycin 8 mg/L and McConkey agar with ciprofloxacin at
2 mg/L) (bioMérieux Benelux B.V., Zaltbommel, The
Netherlands). Isolates were identified by the use of
matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI BioTyper, Bruker Daltonik
GmbH, Leipzig, Germany) according to the manufac-
turer’s instructions.
Susceptibility tests were performed using the Vitek2
system (bioMérieux Benelux B.V., Zaltbommel, The
Netherlands). Antimicrobial susceptibility results were
interpreted according to the EUCAST guidelines (v1.1, v
1.2 from August 2011 and v1.3 from January 2012).
In accordance with an earlier study [3], multiresistance
pattern A was defined as resistance to tobramycin and
to ciprofloxacin or ceftazidime. Multiresistance pattern
B was resistance to tobramycin, to ciprofloxacin and to
ceftazidime.
Gram-negative microorganisms intrinsically non-sus
ceptible to applied antibiotics were excluded from the
analysis: Achromobacter spp. and Stenotrophomonas spp.
for all tested antibiotics; Enterobacter spp. for ceftazi-
dime; Hafnia alvei for ceftazidime; Morganella spp. for
colistin and ceftazidime; Proteus mirabilis for colistin;
Proteus vulgaris for colistin and ceftazidime; Providentia
spp. for aminoglycosides and ceftazidime; Serratia spp.
for colistin and ceftazidime; Citrobacter for ceftazidime.
In a post-hoc analysis we also determined rectal car-
riage rates with all antibiotic-resistant Gram-negative
bacteria (ARGNB), including bacteria intrinsically
non-susceptible to the applied antibiotics.
Statistical analysis
The primary endpoint was time to first colonization with
any Gram-negative bacteria resistant to tobramycin, cef-
tazidime, ciprofloxacin, meropenem or colistin that was
not present at time of ICU discharge. Time to new
colonization with resistant bacteria was compared
between the regimes by Cox proportional hazards model-
ing with adjustment for hospital as a covariate. Differences
in the proportion of patients colonized with resistant bac-
teria were tested by chi-square analysis. Based on earlier
studies, we estimated that 10% of patients would be colo-
nized within 10 days after ICU discharge with any resist-
ant aerobic Gram-negative bacteria [3]: 620 patients per
study group were required to exclude the hypothesis that
colonization with any resistant strain differs more than 5%
between groups (two-sided,alpha 0.05, beta 0.20).
Results
Patient characteristics
During the study period, 1370 patients were discharged
from the ICU to a medical or surgical hospital ward, and
rectal swabs had been obtained from 996 patients (507
during SDD and 489 during SOD) at the day of ICU dis-
charge. Patients in the SOD group more often had
planned ICU admission (22% vs. 16%). Apart from dif-
ferences in referring medical specialty, all other patient
characteristics were comparable (Table 1). Mean ICU
length of stay was 13.4 ± 13.8 days in patients treated
with SOD and 12.8 ± 12.4 days in patients treated with
SDD (p = 0.52), and 87.9% and 87.9% (SDD and SOD, re-
spectively) of the patients survived the hospital stay.
Resistance prevalence at ICU discharge
Rectal colonization with a Gram-negative bacterium re-
sistant to any of the phenotypes investigated at the time
of ICU discharge in the three hospitals ranged from
3.4% to 5.2% after SDD and from 10.7% to 30.6% after
SOD, yielding pooled estimates of 4.1% and 17.8% after
SDD and SOD, respectively (p < 0.0001) (Table 2). For
individual antibiotics, prevalence of resistance was high-
est for ceftazidime (9.4% with SOD versus 1.8% with
SDD, p < 0.0001). Carriage of extended spectrum
beta-lactamase (ESBL)-producing bacteria was demon-
strated in 12.3% of patients treated with SOD and 1.4%
of patients treated with SDD (p < 0.0001). Prevalence of
resistance against meropenem was 0.6% with SOD and
0% with SDD (p = 0.23) and against colistin it was 2.0%
with SOD and 1.0% with SDD (p = 0.27). Detailed data
about resistance phenotype for different bacteria are
given in Additional file 1. In post-hoc analysis the preva-
lence of rectal colonization with any ARGNB, including
intrinsically resistant bacteria, at ICU discharge was
4.9% after SDD and 22.3% after SOD (p < 0.0001)
(Additional file 2).
Acquisition of resistance after ICU discharge
Occurrence of newly acquired colonization was studied
in 835 patients (426 treated with SDD and 409 treated
with SOD), with carriage determined at ICU discharge
and at least one successive time point thereafter (Fig. 1).
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The mean follow up of these patients was 7.9 ± 3.9 in
the SDD and 7.5 ± 4.0 days in the SOD group. The
mean number of rectal swabs obtained per patient was
3.1 ± 0.9 after SDD and 3.3 ± 1.0 after SOD.
The primary endpoint of this study, i.e. a new epi-
sode of colonization with any Gram-negative bacteria
resistant to ceftazidime, tobramycin, ciprofloxacin,
meropenem or colistin was reached in 41 of 426 pa-
tients in the SDD group and in 64 of 409 patients in
the SOD group (p = 0.01, Table 2). The mean time
until colonization was 6.5 days with SDD and 4.8 days
with SOD. The hazard ratio for acquiring new car-
riage after SDD, compared to SOD and adjusted for
ICU, was 0.61 (95% CI 0.40–0.91, p = 0.02 by Cox re-
gression analysis), the cumulative risks of acquisition
at day 10 were 13% and 18% after SDD and SOD re-
spectively (Fig. 2). In post-hoc analysis of all ARGNB,
including intrinsically resistant bacteria, the hazard
ratio for acquiring new carriage with ARGNB after
SDD, compared to SOD, and adjusted for ICU, was
0.78 (95% CI 0.55–1.11, p = 0.16 by Cox regression
analysis, Fig. 3).
Table 1 Baseline characteristics
SOD (n = 489) SDD (n = 507) p value
Characteristic
Mean age (mean + SD) (years) 59.5 + 15.6 59.6 + 15.3 0.93
Male (%) 61.0 63.3 0.51
Planned ICU admission (%) 22.2 16.1 0.03
Surgical 47.0 48.6 0.18
Medical 53.0 51.4 0.18
Apache IV score 75.9 ± 26.3 73.2 ± 27.3 0.22
Referring speciality (%)
Cardiology 8.6 7.3 0.92
Internal medicine 13.6 9.4 0.19
Pulmonology 3.2 4.3 0.30
Neurology 5.8 10.0 0.01
Surgery 20.0 19.0 0.73
Thoracic surgery 27.4 17.7 0.01
Neurosurgery 7.8 10.4 0.07
Other 13.6 21.9 0.01
Mechanical ventilation (%) 90.5 90.7 0.96
CPR before ICU admission 9.0 11.6 0.24
Acute renal failure 9.2 7.9 0.56
Stroke 5.7 9.3 0.06
Confirmed infection at ICU admission 27.1 31.0 0.23
COPD 7.7 9.1 0.54
Diabetes mellitus 11.5 15.4 0.11
Chronic renal failure 5.3 7.7 0.19
Chronic dialysis 1.5 1.2 0.85
Metastasized cancer 2.4 1.9 0.73
Cirrhosis 1.5 0.9 0.61
Immune deficiency 10.5 9.8 0.96
Hematologic cancer 4.0 3.7 0.99
Heart failure III-IV/IV NYHA 7.5 6.1 0.48
Resp. failure III-IV/IV NYHA 5.9 5.1 0.70
ICU length of stay (days) 13.4 ± 13.8 12.8 ± 12.4 0.52
Hospital survival (%) 87.9 87.9 0.92
SDD selective decontamination of the digestive tract, SOD selective oropharyngeal decontamination, APACHE Acute Physiology and Chronic Health Evaluation,
CPR cardiopulmonary resuscitation, COPD chronic obstructive pulmonary disease, NYHA New York Heart Association, Resp. respiratory
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Table 2 Rectal colonization with resistant Gram-negative bacteria at and after ICU discharge and number of resistance phenotypes
(to ceftazidime, tobramycin, colistin, meropenem and ciprofloxacin)
Number of patients colonized with
ARGNB at ICU discharge
Number of patients acquiring colonization
with ARGNB after ICU discharge
SDD (n = 507) SOD (n = 489) p value* SDD (n = 426) SOD (n = 409) p value*
At least one AR-GNB
ICU A 8/154 (5.2%) 29/271 (10.7%) 0.05 14/134 (10.4%) 38/224 (17.0%) 0.09
ICU B 6/115 (5.2%) 38/124 (30.6%) < 0.0001 9/95 (9.5%) 16/96 (16.7%) 0.14
ICU C 8/238 (3.4%) 20/94 (21.3%) < 0.0001 18/197 (9.1%) 10/89 (11.2%) 0.6
All 22/507 (4.3%) 87/489 (17.8%) < 0.0001 41/426 (9.6%) 64/409 (15.6%) 0.01
Different ARGNB 23 97 < 0.0001 66 90 0.02
E.coli 10 46 20 36
Enterobacter sp. 1 11 8 15
K. pneumoniae 1 9 6 4
P. aeruginosa 3 15 6 15
other 8 16 26 20
Resistance phenotypes
Ceftazidime 9 46 21 27
Ciprofloxacin 11 40 12 29
Tobramycin 17 33 23 36
Meropenem 0 3 1 3
Colistin 5 10 7 11
ESBL 7 60 20 24
ARGNB antibiotic resistant Gram-negative bacteria, SDD selective decontamination of the digestive tract, SOD selective oropharyngeal decontamination,
ESBL extended spectrum beta-lactamase
*p value by Chi square analysis for difference between SOD and SDD
Fig. 1 Trial profile. SDD, selective decontamination of the digestive tract; SOD, selective oropharyngeal decontamination
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For individual antibiotics, only the hazard ratio for ac-
quiring carriage of ciprofloxacin-resistant bacteria was
significantly different; for SDD, compared to SOD, 0.48,
95% CI 0.24–0.99; p = 0.05) (Additional file 3). Clinically
relevant or statistically significant differences were not
found for resistance against ceftazidime, tobramycin,
meropenem, and colistin or for ESBL-producing bacteria
and bacteria with multiresistance A and multiresistance
B patterns (Additional file 4).
Newly acquired resistance carriage was most frequently
observed for ciprofloxacin (Additional file 5; 7.1% for
SOD vs. 2.8% for SDD-treated patients, p = 0.007) and
tobramycin (8.8% for SOD and 5.4% for SDD, p = 0.07).
The incidence of new colonization with ESBL-producing
bacteria was 5.9% with SOD patients and 4.7% with SDD
(p = 0.54). Acquired carriage with Gram-negative bacteria
resistant to colistin was observed in 11 (2.7%) and 7
patients (1.6%) in the SOD and SDD groups, respectively
(p = 0.42). It should be noted that in this analysis more
than one different resistant bacteria could be cultured
from individual patients. Escherichia coli was the most fre-
quently cultured resistant microorganism (Table 2 and
Additional file 5; results for post-hoc analysis on all
ARGNB, including intrinsically resistant bacteria in
Additional file 2).
In time, the prevalence of carriage with at least one
ARGNB gradually increased (from 4.3% at T = 0 to 11.3%
at day 10 after SDD, whereas the prevalence after SOD
remained stable between T = 0 and day 6 (17.8–18.9%),
but declined to 12.5% at day 10. At this time point the
prevalence was no longer significantly different between
both groups (p = 0.7) (Table 3 and Additional file 6). The
cumulative number of different resistant bacteria and of
resistance phenotypes to individual antibiotics (ceftazi-
dime, ciprofloxacin, tobramycin, meropenem and colistin)
at the four time points of measurement is shown in
Table 3. After ICU discharge, clearance of ARGNB was
comparable in both groups with 61–82% of cultured
ARGNB still present at the next assessment (Additional
file 7). Acquisition of new ARGNB between different time
points after ICU discharge is shown in Additional file 7.
Discussion
In this study in 996 patients, prevalence of intestinal car-
riage with antibiotic-resistant Gram-negative bacteria at
the time of ICU discharge was higher in patients treated
with SOD, compared to patients who had received SDD
during the ICU-stay, as were acquisition rates with such
bacteria after ICU discharge. Yet, 10 days after ICU dis-
charge the prevalence of intestinal carriage with
antibiotic-resistant Gram-negative bacteria was compar-
able in both patient groups.
In the SDD and SOD groups, acquisition rates of re-
sistant bacteria, not detected at the time of ICU
Fig. 2 Time to first colonization with any Gram-negative bacteria
resistant to tobramycin, ceftazidime, ciprofloxacin, meropenem or
colistin in patients who were not already colonized with that specific
resistant Gram-negative bacteria at time of ICU discharge. Bacteria that
are intrinsically resistant to the antibiotics are excluded. Analysis after
adjustment for individual ICU. p = 0.02 by Cox regression analysis for
the difference between patients treated with selective
decontamination of the digestive tract (dashed line; n = 426) or
selective oropharyngeal decontamination (solid line; n = 409)
Fig. 3 Additional analysis on all antibiotic-resistant Gram-negative
bacteria (ARGNB), including intrinsically resistant bacteria. Time to
first colonization with any Gram-negative bacteria resistant to
tobramycin, ceftazidime, ciprofloxacin, meropenem or colistin in
patients who were not already colonized with that specific resistant
Gram-negative bacteria at time of ICU discharge. Analysis after
adjustment for individual ICU. p = 0.16 by Cox regression analysis for
the difference between patients treated with selective
decontamination of the digestive tract (dashed line; n = 426) or
selective oropharyngeal decontamination (solid line; n = 409)
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discharge, were 13 and 18%, respectively. We are not
aware of similar studies quantifying colonization acquisi-
tion after ICU discharge. It is, therefore, not possible to
establish a causal relationship between SDD or SOD and
these acquisitions, and the observations may also reflect
the carriage dynamics after ICU discharge, irrespective
of administration of prophylactic enteral antibiotics.
Our findings are in accordance with previous studies,
showing that intestinal carriage with antibiotic resistant
Gram-negative bacteria was lower during SDD, compared
to SOD or standard care [2, 3, 9]. In the only study that
systematically monitored intestinal colonization with any
Gram-negative bacteria (resistant or non-resistant) during
SOD, carriage was similar in ICU patients that had re-
ceived SOD and patients that had received standard care
without enteral antibiotics [10]. In that study, SOD,
compared to placebo, was also not associated with differ-
ences in bacterial carriage in gastric aspirates, strongly sug-
gesting that SOD does not modulate the intestinal flora.
Moreover, in unit-wide point-prevalence surveys intestinal
carriage with antibiotic-resistant Gram-negative bacteria
was similar with SOD compared to standard care [3].
This difference in carriage of ARGNBs at the time of
ICU discharge could result from true eradication or sup-
pression of Gram-negative bacteria or from false-negative
culture results due to the presence of antibiotics in mater-
ial obtained for culture. The latter two mechanisms, true
suppression or false-negative cultures, both reflect the
presence of bacteria, yet in quantity not surpassing the
detection limit of semi-quantitative culture methods.
Discontinuation of antibiotic administration, which occurs
after ICU discharge, could then lead to rapid “acquisition”.
Table 3 Rectal colonization with resistant Gram-negative bacteria at ICU discharge and at different time points after ICU discharge
and number of resistance phenotypes (to ceftazidime, tobramycin, colistin, meropenem and ciprofloxacin)
SDD SOD
n Number of patients
colonized with
any ARGNB (%)
Number of resistant
bacteria (range of
different bacteria
per patient)
Cumulative number
of resistance
phenotypes
(average number
per ARGNB)
n Number of
patients
colonized
with any
ARGNB (%)
Number of
resistant (range
of different
bacteria per
patient)
Cumulative number
of resistance
phenotypes (average
number per ARGNB)
ICU discharge 507 22 (4.3) 23 (1–2) 49 (2.1) 489 87 (17.8) 97 (1–2) 195 (2.0)
E. coli 10 46
Enterobacter sp. 1 11
K. pneumoniae 1 9
P. aeruginosa 3 15
other 8 16
Day 3 262 20 (7.6) 21 (1–2) 51 (2.4) 317 63 (19.9) 73 (1–3) 145 (2.0)
E. coli 6 34
Enterobacter sp. 3 9
K. pneumoniae 1 5
P. aeruginosa 2 9
other 9 16
Day 6 326 25 (7.7) 26 (1–2) 51 (2.0) 323 61 (18.9) 64 (1–2) 124 (1.9)
E. coli 7 39
Enterobacter sp. 4 8
K. pneumoniae 1 4
P. aeruginosa 2 4
other 12 9
Day 10 230 26 (11.3) 29 (1–2) 56 (1.9) 224 28 (12.5) 32 (1–2) 61 (1.9)
E. coli 7 15
Enterobacter sp. 1 5
K. pneumoniae 3 1
P. aeruginosa 4 5
other 14 6
Bacteria may have been present at ICU discharge or acquired after ICU discharge
ARGNB antibiotic-resistant Gram-negative bacteria
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Indeed, early acquisition of colonization was demon-
strated within the first few days after ICU discharge, but
this tended to occur more frequently in patients that
had received SOD, compared to SDD. This finding does
not support the hypothesis that lower carriage at the
time of ICU discharge resulted from suppression or
false-negative culture results, although it can not fully be
excluded that the enterally administered antibiotics dur-
ing SDD are present in the 10-day follow-up period, still
suppressing growth of ARGNB from rectal samples.
Unfortunately, we have no data on antibiotic concentra-
tions in stools after ICU discharge.
The prevalence of carriage with antibiotic-resistant bac-
teria in general hospital wards is low in Dutch hospitals. It
is unlikely that treated with SOD were exposed to higher
colonization pressures after ICU discharge. Patients were
discharged to specialty wards depending on bed availabil-
ity and there was no difference in discharge policy be-
tween study periods. As sample collection was restricted
to the included patients the role of cross-colonization in
these acquisition events cannot be determined.
Despite the lower carriage at the time of ICU dis-
charge and the lower hazard for acquiring carriage with
resistant Gram-negative bacteria for SDD patients, car-
riage rates at day 10 after ICU discharge were compar-
able with SDD and SOD. This resulted from gradually
increasing proportions of patients treated with SDD with
carriage, and stable prevalence until day 6 followed by a
decline in prevalence at day 10 in patients treated with
SOD. The higher disappearance rate of resistant bacteria
in patients with the highest prevalence of ARGNBs may
suggest first-order kinetics, i.e. a fixed proportion of re-
sistant bacteria colonizing patients disappears per unit of
time. Absolute disappearance is then more likely to
occur in patients treated with SOD, as they start with a
higher prevalence. Indeed, we found that persistence of
cultured ARGNB in the next sample was 62–82% in
both groups. The rapid clearance of resistant bacteria is
in contrast with findings by Haverkate and co-authors
[11]. They reported that the mean time to clearance of
highly resistant enterobacteriaceae was 1.4 months.
However, whereas we studied all patients discharged
from the ICU, Haverkate and co-authors only included
patients if they were readmitted to the same ICU, poten-
tially resulting in a selected population with a different
case mix of patients.
Our findings provide new - observational - insights
into the intestinal colonization dynamics of ICU pa-
tients that have received SDD or SOD. These dynam-
ics are still largely unstudied, and thus unexplained.
With next-generation sequencing approaches a
marked increase in aminoglycoside-resistance genes
was demonstrated in 12 ICU patients all treated with
SDD, during the course of critical illness [12]. Yet,
whether this increase can be attributed to SDD re-
mains to be determined, as the intestinal resistome of
ICU patients not treated with SDD have not been
studied. Our finding of rapid acquisition of resistant
bacteria after discharge from the ICU and discontinuation
of SDD/SOD could be compatible with a scenario in
which resistance genes accumulate in the non-culturable
flora during the ICU stay and antibiotic exposure,
followed by recolonization with commensal - antibiotic
susceptible - Gram-negative bacteria after discontinuation
of antibiotics in SDD/SOD with subsequent transfer of re-
sistance genes from non-pathogenic anaerobic bacteria to
potentially pathogenic bacteria colonizing the gut. Further
detailed studies on the dynamics of the intestinal resis-
tome are warranted.
In accordance with earlier studies, the predefined
objective of our study was rectal colonization with
ARGNB, excluding bacteria that are intrinsically
non-susceptible to certain antibiotics, e.g. Enterobacter
cloacae, resistant to ceftazidime. Indeed, these bacteria
can not acquire resistance against these antibiotics due
to treatment with SDD/SOD, but antibiotic prophylaxis
might also select for bacteria that are intrinsically
non-susceptible. We, therefore, performed a post-hoc
analysis of all ARGNB, including bacteria that are intrin-
sically resistant. Consequently, colonization prevalence
with ARGNB was higher at each time point, mostly by
an increase in Morganella sp., Citrobacter sp. and
Enterobacter sp. In this post-hoc analysis, colonization at
ICU discharge was lower after SDD compared to SOD,
but the difference in acquisition rates between SDD and
SOD after ICU discharge were similar and no longer sta-
tiscally significant.
There are several study limitations. First, for feasibility
reasons, the period of follow up was limited to 10 days
after ICU discharge and cessation of SDD or SOD. Des-
pite the study size, the study was underpowered to
quantify effects on infections with ARGNB. Further-
more, as the study was performed in three tertiary care
centers we cannot rule out that effects on early
recolonization are different in settings with other patient
populations. Our study was restricted to intestinal car-
riage with antibiotic-resistant Gram-negative bacteria. In
a previous study acquisition of respiratory tract carriage
with antibiotic-resistant Gram-negative bacteria also oc-
curred less frequently in patients that received SDD,
compared to patients receiving SOD or standard care
[13]. Further studies are needed to elucidate the mecha-
nisms underlying those observations.
Our study was performed in three Dutch hospitals, all
considered to have low prevalence of antibiotic resist-
ance, compared to most other countries, which reduces
the generalizability of our findings. How these findings
can be extrapolated to areas with high endemicity of
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(multi)resistant Gram-negative strains remains uncertain.
Recently, a multicenter cluster-randomized trial of decon-
tamination strategies in 13 European ICUs has been com-
pleted. Findings from this trial are not yet available but
will provide more information on the use of SDD and
SOD in areas with higher prevalence of resistance (N.L.
Plantinga and B.H. Wittekamp; personal communication).
A prospective controlled study performed in an area with
a high level of carbapenem-resistant Enterobacteriaceae
(CRE) showed that non-absorbable drugs eradicated CRE
gastrointestinal colonization significantly better than spon-
taneous eradication [14]. In contrast, a retrospective ana-
lysis performed in a Netherlands ICU reported an increase
of colistin-resistant Enterobacteriacaeae after the introduc-
tion of SDD [15]. More research on the effects of SDD
and SOD on infections and mortality and on antibiotic re-
sistance in those areas is needed. Finally, we did not test
for recolonization with methicillin-resistant Staphylococ-
cus aureus (MRSA) and vancomycin-resistant Enterococci
(VRE), due to the very low prevalence in our country [16].
Conclusions
The rate of colonization with resistant Gram-negative bac-
teria (excluding intrinsically resistant bacteria) during ICU
stay is lower in patients using SDD compared to those
using SOD. However, colonization 10 days after ICU dis-
charge was comparable in both groups (13–18%). This
high and rapid acquisition, which was most pronounced
after SOD, has not been shown before. At the same time,
the clearance of resistant bacteria after ICU discharge is
higher after SOD leading to comparable carriage of resist-
ance at 10 days after ICU discharge. This rapid clearance
of resistance is a new finding and more studies are needed
to better understand the complexity of the dynamics of
colonization with resistant bacteria in ICU patients. In
post-hoc analysis of all ARGNB, including intrinsically re-
sistant bacteria, colonization at ICU discharge was lower
after SDD, but the difference in acquisition rates between
SDD and SOD after ICU discharge were similar and no
longer statistically significant.
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